Cambridge Heart

	Cambridge Heart Reports Results for the First Quarter 2008
	Medicare Coverage for Microvolt T-Wave Alternans Testing; Patented Analytic Spectral Method Required
	Premera Blue Cross Covers Microvolt T-Wave Alternans Testing
	Cambridge Heart Announces Changes in the Sales and Marketing Organization
	Cambridge Heart Names Ali Haghighi-Mood, Ph.D., Chief Executive Officer
	Cambridge Heart Releases Statement by Dr. Theodore Chow on MTWA Testing
	Results from the MASTER I Trial to be Presented in Late Breaker at AHA Scientific Session
	ALPHA Supports Use of MTWA Risk Stratification in Non-Ischemic Heart Failure
	Cambridge Heart Welcomes Two New Directors
	Cambridge Heart Expands Co-Marketing Agreement with St. Jude Medical
	Largest Prospective Study of Microvolt T-Wave Alternans in Patients with Non-ischemic Cardiomyopathy Confirms the Predictive Value of MTWA
	Largest Prospective Study of Microvolt T-Wave Alternans Demonstrates This Technology's Predictive Value
	Clinical Trial Demonstrates that MTWA Test is Comparable to Invasive Tests in Identifying Patients Who Could Benefit from ICDs
	Read the article from Nature Clinical Practice Cardiovascular Medicine, ?Can microvolt T-wave alternans testing reduce unnecessary defibrillator implantation??
	More news...